Thymalfasin

Drug Profile

Thymalfasin

Alternative Names: Thymosin-α-1; Tα 1; Zadaxin

Latest Information Update: 27 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas at Austin
  • Developer SciClone Pharmaceuticals; sigma-tau SpA
  • Class Adjuvants; Antineoplastics; Antivirals; Oligopeptides; Thymus hormones
  • Mechanism of Action Immunostimulants; T-lymphocyte subset modulators; Th1 cell stimulants; Th2-cell-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Hepatitis B; Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Malignant melanoma

Highest Development Phases

  • Marketed Cancer; Hepatitis B; Hepatitis C
  • Phase III Sepsis
  • No development reported Hepatocellular carcinoma; Malignant melanoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 16 Sep 2016 SciClone Pharmaceuticals plans a phase I/II trial for Non-small cell lung cancer (Metastatic disease) in Italy (NCT02906163)
  • 11 Mar 2016 SciClone Pharmaceuticals has patent protection for thymalfasin in China (SciClone Pharmaceuticals, Form 10-K, March 2016)
  • 13 May 2015 Discontinued - Phase-III for Hepatitis B in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top